Biofidelity closes Seed round and appoints Dr Heiner Dreismann as Senior Advisor
OTIF portfolio company Biofidelity was spun out of Base4 Innovation in early 2019 to develop high performance novel molecular assays for the sensitive detection of low-frequency genetic mutations.
The Company has announced the close of a £750,000 Seed round from investors including OTIF, Longwall Ventures and an undisclosed US-based multinational diagnostics company, among others. Biofidelity will be led by CEO Dr Barnaby Balmforth, and Director Cameron Frayling, both co-founders of the Company and co-inventors of the proprietary chemistry that underpins Biofidelity’s molecular diagnostic assays.
The Company has attracted Dr Heiner Dreismann, former President and CEO of Roche Molecular Systems, and a leading industry expert in the field of molecular and medical diagnostics, as Senior Advisor.
Click here for the official Company press release.